Quantbot Technologies LP Makes New $1.23 Million Investment in Progyny, Inc. $PGNY

Quantbot Technologies LP purchased a new position in shares of Progyny, Inc. (NASDAQ:PGNY) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 42,486 shares of the company’s stock, valued at approximately $1,225,000. Quantbot Technologies LP owned approximately 0.05% of Progyny at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in PGNY. BlackRock Inc. purchased a new position in shares of Progyny in the second quarter valued at approximately $334,426,000. Wellington Management Group LLP increased its position in shares of Progyny by 260.9% during the fourth quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock worth $57,607,000 after purchasing an additional 1,621,688 shares in the last quarter. Fort Washington Investment Advisors Inc. OH increased its position in shares of Progyny by 46.9% during the first quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company’s stock worth $45,734,000 after purchasing an additional 859,289 shares in the last quarter. Loomis Sayles & Co. L P acquired a new position in Progyny in the 4th quarter valued at $19,917,000. Finally, William Blair Investment Management LLC acquired a new position in Progyny in the 2nd quarter valued at $16,807,000. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Progyny Trading Up 1.5%

Shares of PGNY stock opened at $25.82 on Wednesday. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $33.06. The company’s 50-day moving average price is $29.08 and its 200-day moving average price is $23.55. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of 28.07, a PEG ratio of 1.85 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The firm had revenue of $350.51 million during the quarter, compared to analysts’ expectations of $349.05 million. During the same period last year, the business earned $0.19 earnings per share. Progyny’s revenue was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. As a group, equities research analysts predict that Progyny, Inc. will post 1.19 EPS for the current year.

Progyny announced that its Board of Directors has initiated a share repurchase program on Tuesday, May 26th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the company to purchase up to 10.3% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on PGNY shares. Citizens Jmp upped their target price on shares of Progyny from $30.00 to $31.00 and gave the stock a “market outperform” rating in a report on Monday, May 11th. Weiss Ratings raised shares of Progyny from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, August 13th. BTIG Research boosted their price target on shares of Progyny from $30.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, July 24th. Citigroup reaffirmed an “outperform” rating on shares of Progyny in a research note on Monday, May 11th. Finally, Truist Financial raised their target price on shares of Progyny from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $33.91.

Insider Activity

In other news, EVP Allison Swartz sold 1,199 shares of Progyny stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $25.02, for a total transaction of $29,998.98. Following the sale, the executive vice president owned 83,316 shares of the company’s stock, valued at approximately $2,084,566.32. The trade was a 1.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Geoffrey Clapp sold 1,530 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $25.58, for a total value of $39,137.40. Following the completion of the transaction, the insider owned 59,117 shares in the company, valued at $1,512,212.86. This represents a 2.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 13,563 shares of company stock worth $351,968 in the last 90 days. 9.90% of the stock is owned by corporate insiders.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.